1. Kazemi M, Amani J, Salmanian AH, Forghanifard MM, Aghamollaei H. [Design and Expression of Recombinant HER-2 Antigen as a Marker for Detection of Breast Cancer]. Modares Journal of Medical Sciences: Pathobiology. 2015;17(4):88-99. [Article in Persian] [ Link] 2. Dvir K, Giordano S, Leone JP. Immunotherapy in Breast Cancer. Int J Mol Sci. 2024 Jul; 25(14): 7517. https://doi.org/10.3390/ijms25147517. [ DOI] [ PubMed] 3. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin. 2016 Jan-Feb;66(1):31-42. https://doi.org/10.3322/caac.21320. [ DOI] [ PubMed] 4. Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024 Nov-Dec;74(6):477-95. https://doi.org/10.3322/caac.21863. [ DOI] [ PubMed] 5. Valizadeh Otaghsara SM, Ghorbanzadeh V, Esmaeil Lashgarian H, Hashemzadeh P, Dariushnejad H. Molecular insight in breast cancer metastasis. Yafte. 2020;22(2):71-88. [Article in Persian] [ Link] 6. Golmohammadi R, Pejhan A. [Gene experison of cell proliferative marker Ki67 in breast cancer]. J Gorgan Univ Med Sci. 2011;13(3):65-71. [Article in Persian] [ Link] 7. Sun X, Kaufman PD. Ki-67: more than a proliferation marker. Chromosoma. 2018 Jun;127(2):175-86. https://doi.org/10.1007/s00412-018-0659-8. [ DOI] [ PubMed] 8. Uxa S, Castillo-Binder P, Kohler R, Stangner K, Müller GA, Engeland K. Ki-67 gene expression. Cell Death Differ. 2021 Dec;28(12):3357-70. https://doi.org/10.1038/s41418-021-00823-x. [ DOI] [ PubMed] 9. Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013 Jun;139(2):539-52. https://doi.org/10.1007/s10549-013-2560-8. [ DOI] [ PubMed] 10. Soliman NA, Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol Med. 2016 Dec;13(4):496-504. https://doi.org/10.20892/j.issn.2095-3941.2016.0066. [ DOI] [ PubMed] 11. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011 Aug;22(8):1736-47. https://doi.org/10.1093/annonc/mdr304. [ DOI] [ PubMed] 12. Woo JW, Chung YR, Ahn S, Kang E, Kim EK, Kim SH, et al. Changes in Biomarker Status in Metastatic Breast Cancer and Their Prognostic Value. J Breast Cancer. 2019 Sep;22(3):439-52. https://doi.org/10.4048/jbc.2019.22.e38. [ DOI] [ PubMed] 13. Ragab HM, Samy N, Afify M, El Maksoud NA, Shaaban HM. Assessment of Ki-67 as a potential biomarker in patients with breast cancer. J Genet Eng Biotechnol. 2018 Dec;16(2):479-84. https://doi.org/10.1016/j.jgeb.2018.03.002. [ DOI] [ PubMed] 14. Nishimura R, Osako T, Okumura Y, Tashima R, Toyozumi Y, Arima N. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J Surg Oncol. 2011 Oct;9:131. https://doi.org/10.1186/1477-7819-9-131. [ DOI] [ PubMed] 15. Abdollahiyan Somesaraei T, Heidarpour P. [Prevalence of risk factors for breast cancer in 30-59 year-old women in comprehensive rural health services in Somesara country in 2018]. Nursing and Midwifery Journal. 2020; 17(12):965-74. [Article in Persian] [ Link] 16. Naghi Pour A, Moghimbeigi A, Shirmohamadi N, Soltanian A, Khazaei S, Nick Ceiar S. [Geographical Distribution of Breast Cancer in Hamadan Province during 2008-2015 Using Bayesian Method]. IJE. 2022; 17(4):362-71. [Article in Persian] [ Link] 17. Erić I, Petek Erić A, Kristek J, Koprivčić I, Babić M. Breast cancer in young women: Pathological and Immunohistochemical features. Acta Clin Croat. 2018 Sep;57(3):497-502. https://doi.org/10.20471/acc.2018.57.03.13. [ DOI] [ PubMed] |
